HUM - Educational Analysis * US Equities
Educational Analysis * US Equities

HUM

Earnings behavior, post-earnings drift, and the gap between consensus and the market's real expectation - the educational primer before you look at the institutional verdict.

Educational content only - not investment advice. Nothing on this page is a recommendation to buy or sell any security. Historical patterns do not predict future outcomes. Consult a licensed financial advisor before making any trading decision.
Published byGamma QC editorial
TickerHUM
CategoryEducational primer
Last reviewedNovember 16, 2026
You're viewing an older edition of this page.Read the latest edition →

Business profile & competitive position

Humana Inc. operates as a Louisville, Kentucky-based health company in the Healthcare sector, specifically within the Medical - Healthcare Plans industry. The business is organized around two reportable segments: Insurance and CenterWell. The Insurance segment covers Medicare, state-based Medicaid, individual and employer plans, specialty benefits, military services, and a pharmacy benefit manager. CenterWell is the care delivery arm and includes pharmacy solutions, primary care, and home solutions. As of December 31, 2025, Humana served approximately 15.0 million members in medical benefit plans and another 4.7 million in specialty products. A defining feature of the revenue base is concentration: 83% of 2025 total premiums and services revenue came from contracts with the federal government, including 14% from individual Medicare Advantage contracts in Florida alone covering roughly 1.0 million members.

The competitive position looks materially different when viewed through reported profitability rather than membership scale. Net margin sits at 0.8% and return on equity is 6.7%. Those figures are not the profile of a business currently extracting wide economic profits from its membership base. Instead, they point to a regulated, capital-intensive industry where pricing power is constrained by federal reimbursement rules and medical-cost trends. What competitive strength Humana does possess likely comes from its vertically integrated model—owning both the insurance book and the care delivery assets through CenterWell—and from operating at scale in government-sponsored programs. But the margin and ROE numbers themselves do not confirm a deep moat; they confirm a large, low-margin managed care franchise under earnings pressure.

Financial posture

Humana's current market capitalization is $55.4 billion, and the stock trades at a price-to-earnings ratio of 44.4 based on a price of $461.12. That valuation multiple is high relative to the company's profitability metrics: a 0.8% net margin and 6.7% ROE imply current earnings are a thin slice of revenue, yet the market is pricing the shares at well above the S&P 500's typical multiple. The disconnect suggests the market is either anticipating a material recovery in margins, assigning value to the CenterWell care-delivery franchise, or pricing in long-run demographic demand for Medicare Advantage. At the same time, the beta of 0.74 indicates the stock historically moves less than the broad market, consistent with a defensive, healthcare-services business whose cash flows are tied to recurring premium revenue.

On a technical basis, the stock is trading above its 50-day exponential moving average of $413.90, with the RSI at 68.2—just below the conventional 70 overbought threshold. Combined with the elevated P/E and compressed margin profile, the current snapshot presents a stock where price momentum has outrun near-term fundamentals. Nothing in these figures implies a judgement on fair value; they simply show that the market is currently valuing Humana at a substantial premium to its most recently reported earnings power.

Strategic priorities & outlook

Humana's most recent SEC 10-K filing outlines four operational priorities. The first is to run an integrated care delivery model that combines quality care, high member engagement, and advanced data analytics. The second is to improve the consumer experience by simplifying how members interact with Humana. The third is to engage members more deeply in clinical programs. The fourth is to help providers shift from fee-for-service payments toward value-based arrangements.

Those priorities map directly onto the company's two-segment structure. CenterWell is where the integrated-care strategy is executed on the ground: as of year-end 2025 it operated 350 primary care clinics, employed roughly 1,300 primary care providers, and served about 491,100 patients. The value-based transition is also measurable: approximately 2,260,900 members, or 15.1% of total medical membership, were covered under shared-risk value-based arrangements, and among individual Medicare Advantage members that figure rises to 37.1%. The strategic direction is therefore clear—move beyond a traditional insurer model toward owning more of the care continuum and bearing more outcome-based risk. The 83% federal revenue concentration remains the backdrop, meaning the success of that strategy will ultimately be judged against reimbursement policies and medical-cost discipline in government programs.

Macro & geopolitical exposure

As a Medical - Healthcare Plans company, Humana's risk map is dominated by U.S. federal healthcare policy and reimbursement dynamics rather than traditional industrial or trade exposures. The most relevant macro variables are Centers for Medicare & Medicaid Services rate decisions, changes to Medicare Advantage benchmarking, Medicaid funding levels at the federal and state level, and regulatory scrutiny of supplemental benefits and prior authorization practices. Because the company derives the majority of its premiums from government contracts, shifts in CMS payment rules flow directly into revenue and margin.

Beyond reimbursement, the sector is exposed to medical-cost inflation, utilization trends, and prescription drug pricing policy. Demographics provide a long-term tailwind—an aging population expands the Medicare-eligible pool—but that demand is offset by political pressure to constrain federal healthcare spending and by periodic changes to program design. Interest rates also matter for insurers because investment income on reserves can help offset underwriting pressure, though the effect is generally slower-moving than reimbursement changes. The 0.8% net margin suggests even small adverse movements in these variables can have an outsized impact on reported earnings.

Recent developments

The most recent headlines appeared on November 16, 2026. Business Wire reported that Humana announced pricing terms for offers to purchase for cash certain of its outstanding debt securities, a signal that management is actively managing the liability side of the balance sheet. The same day, Zacks published an article framing Humana as a momentum pick, while defenseworld.net noted that Aberdeen Group plc had decreased its position in the stock. Two days earlier, on November 14, 2026, defenseworld.net also reported that BCV Asset Management Inc. sold 3,090 shares of Humana. These institutional flow items are observations of activity rather than evidence of a consensus direction, but they illustrate that portfolio managers are actively reassessing positions around current price levels.

Earnings behavior & post-earnings drift

Humana has beaten earnings estimates in each of the last eight reported quarters, producing a 100% beat rate with an average surprise of 8.9%. The post-earnings price pattern is also directional: the average 5-day move after earnings across those quarters is +3.31%, classified as an "up" drift. That suggests the stock has tended to absorb the report and drift higher over the following week even when the immediate next-day reaction is muted or negative.

The last four reports illustrate the mechanics. On November 6, 2026, Humana reported a loss of $0.70 per share against an estimate of a $1.00 loss, delivering a 30% positive surprise; the stock fell 2.43% the next day but rose 3.75% over the following five trading days. On July 29, 2026, EPS of $7.61 beat the $7.27 estimate by 4.7%, yet the stock gained only 0.34% the next day and slipped 0.44% over five days. April 29, 2026 saw a $10.31 result versus $10.24 estimated (0.7% surprise), with a 2.75% next-day drop and a 1.32% five-day recovery. The February 11, 2026 report showed a $3.96 loss versus a $4.00 estimated loss (1% surprise), prompting a 1.96% next-day gain and an 8.61% rally over the following five days. The next scheduled report is February 10, 2027, before the market opens, with the current consensus EPS estimate at negative $7.60.

For readers looking to dig deeper, the complete institutional verdict—covering analyst ratings, target ranges, and consensus revisions around the upcoming February 10 report—provides additional context on how professional investors are interpreting this earnings record, the 44.4 P/E, and the 83% federal revenue exposure.

Frequently Asked Questions

What does Humana actually do?

Humana is a health company with two main segments: Insurance, which offers Medicare, Medicaid, employer, and specialty plans; and CenterWell, which provides pharmacy, primary care, and home solutions. As of December 31, 2025, it served about 15.0 million medical benefit members and 4.7 million specialty members.

How has Humana performed around earnings?

Over the last eight quarters Humana has beaten estimates 100% of the time, with an average surprise of 8.9%. The stock has also shown a positive average 5-day post-earnings drift of 3.31%, even though the next-day reaction has sometimes been negative.

Why is Humana's P/E so high relative to its margin?

Humana trades at a P/E of 44.4 despite a 0.8% net margin and 6.7% ROE, suggesting the market is pricing in a future margin recovery, growth in Medicare Advantage membership, or value from the integrated CenterWell care-delivery business—or some combination of all three.

Real Data - Gamma QC Earnings IntelligenceAs of Nov 16, 2026
Humana Inc. · Healthcare / Medical - Healthcare Plans
$55.4BMarket cap
44.4P/E
0.8%Net margin
6.7%ROE
100%Beat rate, last 8Q
8.9%Avg EPS surprise
3.31%Avg 5-day move after earnings
2027-02-10Next earnings
ReportedActualEstimateSurprise1D Move5D Move
2026-11-06$-0.7$-1+30%-2.43%+3.75%
2026-07-29$7.61$7.27+4.7%+0.34%-0.44%
2026-04-29$10.31$10.24+0.7%-2.75%+1.32%
2026-02-11$-3.96$-4+1%+1.96%+8.61%
2025-11-05$3.24$2.93+10.6%--
2025-07-30$6.27$5.92+5.9%--

Previous HUM editions

Beyond the primer

Get the institutional verdict on HUM

Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.

Read the HUM verdict at Gamma QC
$49 Pro / $249 RIA * gammaqc.com

Verify authenticity

Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.